Headlines about MEI Pharma (NASDAQ:MEIP) have been trending somewhat positive on Tuesday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MEI Pharma earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.7699661868829 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of analysts recently issued reports on MEIP shares. Cann reissued an “outperform” rating on shares of MEI Pharma in a research report on Wednesday, May 24th. Oppenheimer Holdings, Inc. started coverage on shares of MEI Pharma in a research report on Thursday, May 25th. They set an “outperform” rating and a $6.50 target price for the company. Finally, Zacks Investment Research downgraded shares of MEI Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th.
Shares of MEI Pharma (NASDAQ:MEIP) traded up 0.74% during mid-day trading on Tuesday, reaching $2.71. 83,268 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $2.72 and a 200-day moving average price of $2.16. MEI Pharma has a 1-year low of $1.34 and a 1-year high of $3.26. The company has a market capitalization of $100.10 million, a P/E ratio of 38.71 and a beta of 1.65.
MEI Pharma (NASDAQ:MEIP) last posted its earnings results on Tuesday, September 5th. The company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. MEI Pharma had a return on equity of 5.26% and a net margin of 11.48%. The firm had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.60 million. On average, equities research analysts forecast that MEI Pharma will post ($1.15) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “MEI Pharma (MEIP) Receives Daily News Impact Rating of 0.24” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/09/19/mei-pharma-meip-receives-daily-news-impact-rating-of-0-24.html.
About MEI Pharma
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.